1. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study
- Author
-
María J. Pedrosa-Martínez, Paloma Gijón, Víctor Moreno-Torres, Consuelo Pedrós, Ferran Torres, Aránzazu Sancho-López, Ana Fernández-Cruz, Francisco Abad-Santos, Enrique Sánchez-Chica, Itziar de Pablo-López, Paulina García-López, Consuelo Rodríguez-Jiménez, Guillermo Prada-Ramallal, Rocío Sanjuan-Jimenez, Ana Aldea-Perona, Carolina Hernández-Carballo, Belén Ruiz-Antorán, Ruth M. Aparicio-Hernández, Lourdes Cabrera-García, E. Montané, Roser Llop-Rius, Josefa A. Aguilar-García, Clara M. Rosso-Fernández, and Evelyn I. Ortiz-Barraza
- Subjects
0301 basic medicine ,Microbiology (medical) ,Relative risk reduction ,musculoskeletal diseases ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,medicine.medical_treatment ,030106 microbiology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Tocilizumab ,Interquartile range ,Internal medicine ,Oxygen therapy ,medicine ,media_common.cataloged_instance ,In patient ,030212 general & internal medicine ,European union ,Mortality ,skin and connective tissue diseases ,media_common ,Original Research ,business.industry ,SARS-CoV-2 ,Hazard ratio ,COVID-19 ,Retrospective cohort study ,medicine.disease ,Pneumonia ,Infectious Diseases ,Respiratory failure ,chemistry ,Steroids ,business ,Cohort study - Abstract
BackgroundWe aimed to determine the impact of tocilizumab use in severe COVID-19 pneumonia mortality.MethodsWe performed a multicentre retrospective cohort study in 18 tertiary hospitals in Spain, from March to April 2020. Consecutive patients admitted with severe COVID-19 treated with tocilizumab were compared to patients not treated with tocilizumab, adjusting by Inverse Probability of the Treatment Weights (IPTW). Tocilizumab effect in patients receiving steroids during the 48h following inclusion was analyzed.ResultsDuring the study period, 506 patients with severe COVID-19 fulfilled inclusion criteria. Among them, 268 were treated with tocilizumab and 238 patients were not. Median time to tocilizumab treatment from onset of symptoms was 11 days (IQR 8-14). Global mortality was 23.7%. Mortality was lower in patients treated with tocilizumab than in controls (16.8% versus 31.5%, HR 0.514 [95CI 0.355-0.744], p< 0.001; weighted HR 0.741 [95CI 0.619-0.887], p = 0.001). Tocilizumab treatment reduced mortality by 14.7% relative to no tocilizumab treatment (RRR 46.7%). We calculated a number necessary to treat of 7. Among patients treated with steroids, mortality was lower in patients treated with tocilizumab than in those treated with steroids alone (10.9% versus 40.2%, HR 0.511 [95CI 0.352-0.741], p = 0.036; weighted HR 0.6 [95CI 0.449-0.804], p< 0.001) (Interaction p = 0.094).ConclusionsThese results show that survival of patients with severe COVID-19 is higher in patients treated with tocilizumab than in those not treated, and that tocilizumab effect adds to that of steroids administered to non-intubated cases with COVID-19 during the first 48 hours of presenting with respiratory failure despite of oxygen therapy. Randomised controlled studies are needed to confirm these results.SummaryWe investigated in-hospital mortality of patients with severe SARS-CoV-2 pneumonia in a multicenter series of patients treated with tocilizumab compared to controls, and adjusted using IPTW. Our results show a beneficial impact of tocilizumab treatment in SARS-CoV-2 pneumonia, that adds to that of steroids.
- Published
- 2020